This page in Swedish

Ola Nilsson

Title: Professor School/office: School of Medical Sciences

Email:

Phone: +46 707 327696

Room: C2107

Ola Nilsson

Research subject

Research environments

  • Diabetes, Endocrinology and Metabolism Research Centre

About Ola Nilsson

Ola Nilsson, MD, PhD is a professor of pediatrics at the Örebro University Hospital evaluating and treating children with endocrine disorders, growth disorders, skeletal diseases and disorders of mineral metabolism.

As a researcher, Ola Nilsson leads a research group focused on regulation of skeletal growth and maturation, as well as disorders of calcium and phosphate metabolism. He has been PI on several clinical studies on rare skeletal disorders and identified aggrecan mutations as a can cause of autosomal dominant short stature with advanced skeletal maturation.

He teaches at the medical school at Örebro University and member of the board for reproduction and development at the medical school program.

He has published more than 60 scientific articles, is an active member of national and international pediatric societies and an frequent lecturer at national and international meetings. He has received several awards from the Pediatric Endocrine Society and the European Society of Pediatric Endocrinology.

 

Publications

Articles in journals |  Articles, reviews/surveys | 

Articles in journals

Kvist, O. F. T. , Luiza Dallora, A. , Nilsson, O. , Anderberg, P. , Sanmartin Berglund, J. , Flodmark, C. & Diaz, S. (2021). A Cross-Sectional Magnetic Resonance Imaging Study of Factors Influencing Growth Plate Closure in Adolescents and Young Adults. Acta Paediatrica, 110 (4), 1249-1256.
Sandberg, J. T. , Ols, S. , Löfling, M. , Varnaitė, R. , Lindgren, G. , Nilsson, O. , Rombo, L. , Kalén, M. & et al. (2021). Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination. Journal of Immunology, 207 (4), 1033-1043.
Baroncelli, M. , Raimann, A. , Padidela, R. & Nilsson, O. (2021). Bone, Growth Plate and Mineral Metabolism. Hormone Research in Paediatrics, 94 (Suppl. 1), 22-22.
Padidela, R. , Cheung, M. , Allgrove, J. , Bacchetta, J. , Semler, O. , Heubner, A. , Schnabel, D. , Emma, F. & et al. (2021). BUR-CL207: An Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with XLH. Hormone Research in Paediatrics, 94 (Suppl. 1), 226-226.
Ain, N. U. , Baroncelli, M. , Costantini, A. , Ishaq, T. , Taylan, F. , Nilsson, O. , Mäkitie, O. & Naz, S. (2021). Novel form of rhizomelic skeletal dysplasia associated with a homozygous variant in GNPNAT1. Journal of Medical Genetics, 58 (5), 351-356.
Dou, Z. , Chau, M. , Muder, D. , Vedung, T. & Nilsson, O. (2021). Optimized protocols for in situ hybridization, immunohistochemistry, and immunofluorescence on skeletal tissue. Acta Histochemica, 123 (5).
Padidela, R. , Whyte, M. P. , Glorieux, F. H. , Munns, C. F. , Ward, L. M. , Nilsson, O. , Portale, A. A. , Simmons, J. H. & et al. (2021). Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 108, 622-633.
Hallgrimsdottir, S. & Nilsson, O. (2021). Premature epiphyseal fusion induced by a retinoic acid agonist in a young girl with fibrodysplasia ossificans progressiva. Hormone Research in Paediatrics, 94 (Suppl. 1), 95-95.
Dou, Z. , Muder, D. , Baroncelli, M. , Bendre, A. , Gkourogianni, A. , Ottosson, L. , Vedung, T. & Nilsson, O. (2021). Rat perichondrium transplanted to articular cartilage defects forms articular-like, hyaline cartilage. Bone.
Gerver, W. J. M. , Gkourogianni, A. , Dauber, A. , Nilsson, O. & Wit, J. M. (2020). Arm Span and Its Relation to Height in a 2- to 17-Year-Old Reference Population and Heterozygous Carriers of ACAN Variants. Hormone Research in Paediatrics, 93 (3), 164-172.
Ain, N. U. , Muhammad, N. , Dianatpour, M. , Baroncelli, M. , Iqbal, M. , Fard, M. A. F. , Bukhari, I. , Ahmed, S. & et al. (2020). Biallelic TMEM251 variants in patients with severe skeletal dysplasia and extreme short stature. Human Mutation, 42 (1), 89-101.
Kvist, O. F. T. , Dallora, A. L. , Nilsson, O. , Anderberg, P. , Berglund, J. S. , Flodmark, C. & Diaz, S. (2020). Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee. Acta Radiologica Open, 9 (9).
Gkourogianni, A. , Andrade, A. C. , Jonsson, B. , Segerlund, E. , Werner-Sperker, A. , Horemuzova, E. , Dahlgren, J. , Burstedt, M. & et al. (2020). Pre- and postnatal growth failure with microcephaly due to two novel heterozygous IGF1R mutations and response to growth hormone treatment. Acta Paediatrica, 109 (10), 2067-2074.
Padidela, R. , Nilsson, O. , Makitie, O. , Beck-Nielsen, S. , Ariceta, G. , Schnabel, D. , Brandi, M. L. , Boot, A. & et al. (2020). The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet Journal of Rare Diseases, 15 (1).
Högler, W. , Imel, A. , Whyte, P. , Munns, C. , Anthony, P. , Ward, L. , Simmons, H. , Padidela, R. & et al. (2019). BUROSUMAB RESULTED IN GREATER IMPROVEMENT IN PHOSPHATE METABOLISM, RICKETS, GROWTH, AND MOBILITY THAN CONTINUATION WITH CONVENTIONAL THERAPY IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH). Osteoporosis International, 30 (Suppl. 2), S409-S410.
Imel, E. A. , Glorieux, F. H. , Whyte, M. P. , Munns, C. F. , Ward, L. M. , Nilsson, O. , Simmons, J. H. , Padidela, R. & et al. (2019). Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet, 393 (10189), 2416-2427.
Beck-Nielsen, S. S. , Mughal, Z. , Haffner, D. , Nilsson, O. , Levtchenko, E. , Ariceta, G. , de Lucas Collantes, C. , Schnabel, D. & et al. (2019). FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet Journal of Rare Diseases, 14 (1).
Nilsson, O. , Whyte, M. P. , Imel, E. A. , Munns, C. , Portale, A. A. , Ward, L. , Simmons, J. H. , Padidela, R. & et al. (2018). Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH) - A Randomized Controlled Phase 3 Study. Hormone Research in Paediatrics, 90 (Suppl.1), 57-58.
Gkourogianni, A. , Segerlund, E. , Hallgrimsdottir, S. , Nilsson, O. & Stattin, E. (2018). Clinical and Radiological Manifestations in a Large Swedish Family with a Pathogenic Heterozygous ACAN Variant. Hormone Research in Paediatrics, 90 (Suppl.1), 424-424.
Lui, J. C. , Barnes, K. M. , Dong, L. , Yue, S. , Graber, E. , Rapaport, R. , Dauber, A. , Nilsson, O. & et al. (2018). Ezh2 mutations found in the Weaver overgrowth syndrome cause a partial loss of H3K27 histone methyltransferase activity. Journal of Clinical Endocrinology and Metabolism, 103 (4), 1470-1478.
Nilsson, O. (2018). It Is Not Just the Growth Hormone-IGF-I Axis. Hormone Research in Paediatrics, 90 (Suppl.1), 12-13.
Jee, Y. H. , Wang, J. , Yue, S. , Jennings, M. , Clokie, S. J. H. , Nilsson, O. , Lui, J. & Baron, J. (2018). Mir-374-5p, mir-379-5p, and mir-503-5p regulate proliferation and hypertrophic differentiation of growth plate chondrocytes in male rats. Endocrinology, 159 (3), 1469-1478.
Nilsson, O. (2018). PRO - To Prime Or Not to Prime?. Hormone Research in Paediatrics, 90 (Suppl.1), 18-19.
Tatsi, C. , Gkourogianni, A. , Mohnike, K. , DeArment, D. , Witchel, S. , Andrade, A. C. , Markello, T. C. , Baron, J. & et al. (2017). Aggrecan Mutations in Nonfamilial Short Stature and Short Stature Without Accelerated Skeletal Maturation. Journal of the Endocrine Society, 1 (8), 1006-1011.
Gkourogianni, A. , Andrew, M. , Tyzinski, L. , Crocker, M. , Douglas, J. , Dunbar, N. , Fairchild, J. , Funari, M. F. A. & et al. (2017). Clinical characterization of patients with autosomal dominant short stature due to aggrecan mutations. Journal of Clinical Endocrinology and Metabolism, 102 (2), 460-469.
Jee, Y. H. , Andrade, A. C. , Baron, J. & Nilsson, O. (2017). Genetics of Short Stature. Endocrinology and metabolism clinics of North America (Print), 46 (2), 259-281.
Andrade, A. C. , Gkourogianni, A. , Segerlund, E. , Werner-Sperker, A. , Horemuzova, E. , Dahlgren, J. & Nilsson, O. (2017). Short Stature Due To Two Novel Heterozygous Igf1r Mutations and Response To Gh Treatment. Hormone Research in Paediatrics, 88 (Suppl. 1), 130-131.
Lui, J. C. , Garrison, P. , Nguyen, Q. , Ad, M. , Keembiyehetty, C. , Chen, W. , Jee, Y. H. , Landman, E. & et al. (2016). EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy. Nature Communications, 7.

Articles, reviews/surveys

Jee, Y. H. , Baron, J. & Nilsson, O. (2018). New developments in the genetic diagnosis of short stature. Current opinion in pediatrics, 30 (4), 541-547.
Andrade, A. C. , Jee, Y. H. & Nilsson, O. (2017). New Genetic Diagnoses of Short Stature Provide Insights into Local Regulation of Childhood Growth. Hormone Research in Paediatrics, 88 (1), 22-37.